BiomEdit Expands Its Veterinary Biologics Portfolio with Folium Science Acquisition

On August 25, 2026, BiomEdit, a leader in the animal health biotechnology space, announced a significant acquisition that promises to transform its operational capabilities. The company has acquired Folium Science's innovative technology platform and pipeline assets, which includes an essential poultry feed additive called BiomElix® One. This formulation has already received approval from Brazil's Ministry of Agriculture and Livestock, marking a strategic expansion in BiomEdit's product offerings.

A New Era for Animal Health

BiomEdit is making waves in the animal health industry by introducing a groundbreaking category known as Programmable Veterinary Biologics™. These biologics are genetically engineered to perform specific biological functions in animals. By acquiring Folium Science's Guided Biotics® CRISPR-Cas technology, BiomEdit strengthens its toolkit to target particular bacterial populations within the microbiome while also retaining the integrity of the overall microbial ecosystem. This dual approach significantly enhances the company's ability to address various health challenges in animal populations.

Strengthening the Research Team

Aaron Schacht, the CEO of BiomEdit, expressed enthusiasm over this acquisition, noting that Folium assembled a world-class scientific team and created a platform that complements BiomEdit's existing technology. Folium's approach to engineering beneficial bacteria to fulfill targeted biological functions dovetails seamlessly with BiomEdit's mission. Schacht highlighted the importance of having a broader set of tools to combat crucial health issues affecting livestock and companion animals.

Focused Programs for Poultry

This acquisition enables BiomEdit to diversify its portfolio in poultry health. The company’s flagship candidate, BE-101, is currently in the final stages of the conditional licensure process with the U.S. Department of Agriculture's Center for Veterinary Biologics (USDA CVB). This product is aimed at preventing mortality associated with necrotic enteritis in broiler chickens, a significant issue for poultry farmers. The inclusion of BiomElix® One enables BiomEdit to offer an approved feed additive, adding tangible value to its array of offerings for animal nutrition and health.

Ed Fuchs, co-founder of Folium Science, remarked on the strong foundation laid by Folium over the past decade. He expressed confidence that BiomEdit is the ideal partner to realize the full potential of their scientific advancements in the sphere of animal health. Fuchs noted the vision and capability that BiomEdit possesses, advocating for the future success of these technologies.

The Bigger Picture

This merger represents more than just an expansion of product lines; it signifies the unification of different scientific methodologies under one umbrella. Schacht emphasizes that this broader toolkit will empower the company to design precise and innovative solutions that cater to the needs of the veterinary community, bridging gaps in animal health and productivity.

With the transaction's financial details undisclosed, industry experts predict that this acquisition may stimulate further advancements in the veterinary biotech realm. As BiomEdit capitalizes on its new capabilities, it aims at providing not only effective solutions for disease prevention but also contributes to the sustainability and overall health of animal populations globally.

About BiomEdit

Founded in 2022, BiomEdit is committed to pioneering solutions in animal health with a focus on engineered microbial strains that tackle specific biological activities. Backed by top-tier investors such as Anterra Capital, Viking Global Investors, and Nutreco, BiomEdit is on a trajectory to reshape animal health through innovation. As the company forges ahead, its prospects in infectious diseases and chronic health issues in livestock and pets continue to expand.

For more information on BiomEdit and its initiatives, visit Biomedit.com.